TY  - JOUR 
AU  - Dimopoulos, Meletios A.
AU  - Tedeschi, Alessandra
AU  - Trotman, Judith
AU  - García Sanz, Ramón
AU  - Macdonald, David
AU  - Leblond, Veronique
AU  - Mahe, Beatrice
AU  - Herbaux, Charles
AU  - Tam, Constantine
AU  - Orsucci, Lorella
AU  - Palomba, M. Lia
AU  - Matous, Jeffrey V.
AU  - Shustik, Chaim
AU  - Kastritis, Efstathios
AU  - Treon, Steven P.
AU  - Li, J.
AU  - Salman, Zeena
AU  - Graef, Thorsten
AU  - Buske, Christian
PY  - 2018
SN  - 0028-4793
UR  - http://hdl.handle.net/10366/155425
AB  - [EN]Single-agent ibrutinib has shown substantial activity in patients with relapsed Waldenström's macroglobulinemia, a rare form of B-cell lymphoma. We evaluated the effect of adding ibrutinib to rituximab in patients with this disease, both in those...
LA  - eng
PB  - NEJM Group
KW  - Waldenstrom macroglobulinemia
KW  - Ibrutinib
KW  - Rituximab
KW  - Randomized trial
KW  - Disease-Free Survival
KW  - Adenine
KW  - Aged
KW  - Adult
KW  - Humans
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Middle Aged
KW  - Hemoglobins
KW  - Waldenstrom Macroglobulinemia
KW  - Pyrazoles
KW  - Pyrimidines
KW  - Atrial Fibrillation
KW  - Immunoglobulin M
KW  - Survival Analysis
KW  - Piperidines
TI  - Phase 3 trial of ibrutinib plus rituximab in Waldenström's macroglobulinemia
DO  - 10.1056/NEJMoa1802917
T2  - New England Journal of Medicine
VL  - 378
M2  - 2399
ER  -